StemCell Therapy

The worlds biggest listed pure-play stem cell developer has a busy slate of clinical work, notably in therapies for advanced heart failure, chronic back pain and graft-versus-host disease (GvHD).

Now these programs are approaching a thrilling denouement and, as the Demtel man enthused, theres more: Mesoblast (ASX:MSB) is also undertaking an expanded coronavirus trial after a 12-patient effort showed promising results in treating acute respiratory distress syndrome (Ards), the usual cause of death with COVID-19.

The patients received infusions of Mesoblasts allogeneic (off the shelf) mesenchymal stem cell candidate, remestemcel-L, acquired from Osiris for $106m in 2013.

Meanwhile, results from two phase III trials are expected this (September) quarter: a 566-patient effort for chronic heart failure and a 404-patient trial for chronic lower back pain caused by disc degeneration.

And in September, the US Food and Drug Administration will rule on whether or not the company can market its GvHD therapy on American shores.

Mesoblast founder and CEO Prof Silviu Itescu notes that across all its therapies the company is targeting the most severe cases where alternative therapies dont exist.

Mesoblasts proprietary process selects precursor and stem cells from the bone marrow of healthy adults, creating a master cell bank. This cell kitty is then expanded into thousands of doses for off-the-shelf use, without the need for tissue matching.

Mesoblast is targeting a common market across all its disease indications: inflammation. In the case of heart disease, tissue macrophages (cells) churn out inflammatory factors that damage heart muscle and cause fibrosis and vascular dysfunction.

The stem cells respond to severe inflammation by switching the culprit macrophages off and converting them to nice cells that actually protect the heart muscle.

This is the central mechanism in each of our disease states: heart failure, back pain, GvHD and rheumatoid arthritis, Professor Itescu says. We have the potential to make a big difference in some very big disease states where inflammation is central.

Backed by the Pratt familys listed investment vehicle Thorney Investments, Mesoblast debuted on the ASX in 2004 and reached a peak valuation of $2.5bn in 2011 before suffering a reality check.

Culprits included a phase II heart trial that failed to meet primary endpoints, a badly executed Nasdaq listing and Israel pharma house Teva Pharmaceuticals decision to walk away from a heart program partnership in 2016.

Mesoblast dual listed on the Nasdaq in November 2015, accompanied by a $US63m capital raising.

The companys Ards and GvHD programs are based on mesenchymal stem cell assets acquired from US pharma group Osiris Therapeutics in October 2013.

Mesoblasts own-developed cells are called mesenchymal precursor cells and they are being developed for rheumatoid arthritis and diabetic nephropathy, as well as the aforementioned heart failure and lower back pain programs.

Ards is bought on by an excessive immune response to the virus in the lungs. The immune cells produce inflammatory cytokines, which destroy lung tissue and can also damage the liver, kidney and heart.

Remestemcell-L has the potential to tame the cytokine storm in Ards and may offer a life-saving treatment for those unfortunate individual sufferers of COVID-19 Ards, Professor Itescu says.

Mesoblasts COVID-19 proclamations have been coming so thick and fast that its been Ard(s) just to keep up. But the core excitement cluster was around Mesoblasts April 23 disclosure of the results of the trial at New Yorks Mt Sinai Hospital, covering moderate to acute Ards cases.

Under the compassionate use protocol, the patients were treated with two infusions of remestemcel-L over the first five days.

The results? Nine of the 12 patients came off a ventilator within a median 10 days, with 83 per cent survival (the Grim Reapers spin on this is that two of them died).

In comparison, only 9 per cent of patients at one reference hospital (38 out of 445 patients) were able to come off the ventilator with standard-of-care treatment.

Another US hospital reported that only 38 patients of 320 or 12 per cent survived.

Of course, 12 people good and true are adequate numbers for a jury, but sub-optimal to comprise a statistically significant trial.

Thus, the company is enrolling 300 patients in a phase III, randomised, controlled trial of severe Ards patients at 30 sites.

The first patients were dosed in early May, with about 15 sites established as the company chases the disease from the northeast to the southern states.

Mesoblast chief medical officer Professor Fred Grossman says the company is carefully choosing hot spots such as Alabama which, as of late May had the no vacancy signs outside its intensive care wards.

The sites are recruiting quite quickly, he says. There is a tremendous interest in this study.

The trial leaders will undertake an interim analysis at 30 days, and when 30 per cent of patients have reached their primary endpoint. At that point the trial can be dumped on futility grounds, or expanded to the control group because it appears to be working.

Remestemcell-L has investigational new drug (IND) status with the US Food and Drug Administration, meaning the company swiftly can initiate trials on patients with very dismal prospects.

Long-suffering Mesoblast investors will recall that the companys shares tumbled 28 per cent in November 2018 after a 159-patient trial of Rexlemestrocel-L (Revascor) for end-stage heart failure did not meet its primary endpoint of weaning patients from left ventricle assist devices (LVADs or heart pumps).

The company claimed the endpoint was set by the independent !!! investigators and was of little real clinical interest. What really mattered was that the trial showed reduced gastrointestinal bleeding by 76 per cent and hospitalisations by 65 per cent.

Investors are now nervously awaiting the first readout of the broader 566-patient chronic heart failure trial across 59 US sites.

Mesoblast targeted patients with class three or four disease, the sickest 15 to 20 per cent of patients who have failed standard-of-care drugs.

Class three patients have a 20 per cent chance of dying within two years while with class four its a case of flip a coin that you will be around in 12 months.

At this stage, Mesoblast retains its heart treatment rights except in China, where it is partnered with Tasly Pharmaceutical.

Mesoblasts phase III back pain trial aimed to enroll 404 patients with lower back pain caused by degenerative disc disease.

The endpoint of the trial, dubbed MPC-06-ID, is an improvement in pain and function over 24 months.

As with the heart trial, results are imminent and its a toss-up as to what release will hit the ASX announcements feed first.

The company is liaising with its global back pain partner Grunenthal GmbH about the clinical protocol for a European phase III confirmatory trial.

In Japan, Mesoblast is partnered with JCR Pharmaceutical for its approved GvHD treatment called Temcell and its off and racing in that smallish but enthusiastic market.

Meanwhile, the company is angling to enter the US market for a similar GvHD treatment, branded Ryoncil.

GvHD afflicts about half of the 30,000 patients annually undergoing allogeneic bone marrow transplant, typically for blood cancers, with their bodies rejecting the alien transplant.

In March, the FDA granted priority review with a September 30 action date, but we might have a good idea of the outcome in August.

Why? Because thats when the FDAs relevant advisory committee meets to vote on the matter and the (virtual) gathering is open to the public.

A date is yet to be set. While advisory committee views are not binding on the FDA, they usually presage the final decision.

If approved, Mesoblast could be selling Ryoncil in the US by the time were carving the Christmas turkey (badly, in the case of your columnist).

Buoyed by the COVID-19 results, Mesoblast in May wasted no time tapping institutional investors for an idle $US90m ($129.6m) in a placement.

Mesoblast already had a healthy cash balance of $US60m.

The raising was struck at $3.20 a share, a modest 7 per cent discount to the prevailing price.

The funds, in the main, will be used to scale-up manufacturing of remestemcell-L and to support the phase III trial, as well as for working capital and general corporate purposes.

The company also has $US67m available through existing financing facilities and partnerships.

Mesoblast reported revenue of $US31.45m for the nine months to March 2020, up 113 per cent. The reported loss narrowed 34 per cent to $US45.3m, reflecting curtailed research and development spend by $US7.5m, or 15 per cent.

The revenue included $US5.9m of JCR royalties from Temcell sales in Japan and milestone revenue of $US25m.

The company stands to pocket up to $US150m of royalties and milestones from Grunenthal prior to any European launch of Revascor.

Successful sales could result in up to $US1bn in milestone payments.

Over the last decade, Mesoblasts ASX shares have traded as high as $9 (October 2011) and as low as $1.03 (December last year).

To the Meso-sceptics the company has promised far too much with limited commercial success, while raising $1bn since listing 16 years ago.

Dare we say that Mesoblast now looks more focused and to be getting somewhere?

When we last covered Mesoblast in March 2019, Professor Itescu said he was 95 per cent certain the company would do what no other Aussie biotech in phase III had done: win FDA drug approval.

Well, Clinuvel has stolen that Aussie first honour, but Mesoblast is well placed to get over the line with a GvHD treatment in the US, which presents a market eight times the size of Japans.

Its certainly rare for a biotech to expect results for three major trials and a key regulatory decision in the space of months.

If the heart and back pain results are definitively positive and the FDA green lights GvHD, the company hits the jackpot. If two or more of them bomb lets not go there.

Your ultra conservative columnist regards the COVID-19 stuff as the icing on the cake with an outside chance of success, especially given the hundreds of other programs in the coronavirus-busting sector.

Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. But he hopes to become proficient in turkey carving by December 25.

This column first appeared in Biotech Daily.

Get the latest Stock & Small Caps news and insights direct to your inbox.

It's free. Unsubscribe whenever your want.

You might be interested in

Original post:
Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision - Stockhead

With the number of people affected by autoimmune diseases on the rise, Executive Medicine of Texas is dedicated to help. Their new Autoimmune Concierge Program is aimed at diagnosing and treating patient who may have begun to lose hope.

SOUTHLAKE, Texas (PRWEB) July 07, 2020

The National Institutes of Health reports that as much as 7% of the American population is suffering from some sort of autoimmune disease, equal to about 23.5 million Americans. They also report that the prevalence of such diseases continues to rise.

Executive Medicine of Texas, a company that's renowned for their half-day executive physicals and all-inclusive concierge packages, knows first-hand how much damage an untreated autoimmune condition can do. "Autoimmune diseases are notorious for causing chronic inflammation. We know that this inflammation can lead to heart disease, cancer, and a number of other serious health complications," says Walter Gaman, MD. "That's why we have to get these patients diagnosed and treated as soon as possible.

Dr. Gaman, one of the founders of the practice, knows first hand how complicated these conditions can be, as he has dealt with his own diagnosis of celiac disease for almost two decades. "I was diagnosed long before patients were being screened so regularly for the disease. Sometimes we study conditions because we want to, and sometimes it's because we have to. Mine started as the latter, but now I study and treat autoimmune disease because I know I can make a difference in the lives of these patients."

Lyme disease, another common autoimmune condition, accounts for much of the rise in this category of illness. The Center for Disease Control reported that there are approximately 329,000 new cases per year in the United States. Mark Anderson, MD said, "When our CEO came down with neuro lyme disease a few years back, it certainly got our attention. Subsequently, we began to see more patients with lyme-like symptoms, many of which tested positive. While not all have long term affects from this disease, many do. That's why proper management is so important."

Celiac and lyme disease are not the only illnesses that fall into this category, there are over 80 conditions that belong to the autoimmune family. Since symptoms can be wide-spread and often mimic other conditions, patients are often misdiagnosed prior to finding the correct diagnosis and form of treatment.

The Autoimmune Concierge Program at Executive Medicine starts with a half-day exam with over one hundred different lab values, some of which are specific for these types of conditions. Because autoimmune disease can cause a host of other health problems, the patients are also screened for cardiac and autonomic nervous system abnormalities. "The goal," Dr. Gaman says, "is to listen to the patient, gather all the right information through extensive testing, and then develop a plan to help them live a healthier and longer life. Part of that plan will be to significantly reduce inflammation and repairing damage when possible."

About:Executive Medicine of Texas is a luxury medical practice that focuses on preventative and proactive medicine. Their clients come from all over the globe and include individuals, as well as many corporate clients. Located in Southlake, Texas, half-way between Dallas and Fort Worth, many patients fly in to DFW airport or one of the many private airports within the area. You can obtain a FREE copy of their award-winning book Age to Perfection: How to Thrive to 100, Happy, Healthy, and Wise by clicking HERE.

For the original version on PRWeb visit: https://www.prweb.com/releases/executive_medicine_of_texas_announces_new_autoimmune_disease_program/prweb17240078.htm

Read more:
Executive Medicine of Texas Announces New Autoimmune Disease Program - Benzinga

GENEVA/LONDON (Reuters) - The World Health Organization (WHO) should soon get results from clinical trials it is conducting of drugs that might be effective in treating COVID-19 patients, its Director General Tedros Adhanom Ghebreyesus said on Friday.

World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus attend a news conference organized by Geneva Association of United Nations Correspondents (ACANU) amid the COVID-19 outbreak, caused by the novel coronavirus, at the WHO headquarters in Geneva Switzerland July 3, 2020. Fabrice Coffrini/Pool via REUTERS

Nearly 5,500 patients in 39 countries have so far been recruited into the Solidarity trial, he told a news briefing, referring to clinical studies the U.N. agency is conducting.

We expect interim results within the next two weeks.

The Solidarity Trial started out in five parts looking at possible treatment approaches to COVID-19: standard care; remdesivir; the anti-malaria drug touted by U.S. President Donald Trump, hydroxychloroquine; the HIV drugs lopinavir/ritonavir; and lopanivir/ritonavir combined with interferon.

Earlier this month, it stopped the arm testing hydroxychloroquine, after studies indicated it showed no benefit in those who have the disease, but more work is still needed to see whether it may be effective as a preventative medicine.

Mike Ryan, head of the WHOs emergencies programme, said it would be unwise to predict when a vaccine could be ready against COVID-19, the respiratory disease caused by the novel coronavirus that has killed more than half a million people.

While a vaccine candidate might show its effectiveness by years end, the question was how soon it could be mass produced, he told the U.N. journalists association ACANU in Geneva.

There is no proven vaccine against the disease now, while 18 potential candidates are being tested on humans.

WHO officials defended their response to the virus that emerged in China last year, saying they had been driven by the science as it developed. Ryan said what he regretted was that global supply chains had broken, depriving medical staff of protective equipment.

I regret that there wasnt fair, accessible access to COVID tools. I regret that some countries had more than others, and I regret that front-line workers died because of (that), he said.

He urged countries to get on with identifying new clusters of cases, tracking down infected people and isolating them to help break the transmission chain.

People who sit around coffee tables and speculate and talk (about transmission) dont achieve anything. People who go after the virus achieve things, he said.

Editing by Michael Shields and Andrew Cawthorne

Read this article:
WHO sees first results from COVID drug trials within two weeks - Reuters

Omar P. Haqqani, for the Daily News

Dr. Haqqani: Eliminating disparity in health care

The medical community should make every effort to eliminate the impact of racism in health care. Although the disparities are being brought to light by the current pandemic, the problem has been acknowledged in the past. Now is the time for health care professionals to aggressively seek to reverse the impact of negative attitudes and practices that have long been in place.

Causes and effects of racism in health care

There is an alarmingly high national rate of COVID-19 hospitalizations and deaths within the minority community, according to The Centers for Disease Control and Prevention. It is 4.5% higher for African Americans than that of the non-minority population. It also rises for Hispanic or Latino individuals and Native Americans.

Aside from the increases brought to light by the coronavirus, the disparity in general good health can be seen across the board in every medical arena. The higher rates of diabetes, obesity, hypertension and other conditions among minorities have contributed not only to higher coronavirus consequences, but to cardiovascular issues, kidney failure and other dangerous circumstances.

In a report published in the archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health's National Library of Medicine in 2019, unequal access to medical care for minorities is a major factor in fostering health inequities. Other factors in maintaining or widening the gap include a lack of childhood development, a higher rate of poverty, and income inequality between minority workers and non-minority workers. Housing and other social and economic factors are also important in the health care disparity discussion. While they may not all seem related specifically to medical care, they result in inadequate circumstances for minorities.

Lack of preventative care

The economic disadvantages more frequently faced by minorities in childhood and adulthood lead to less consistent medical care. Infrequent checkups and less education about signs of disease increase the odds of major health difficulties. According to the NIH/NLM report, only 3% of all health care money in the United States is spent on preventative care. Many dangerous medical conditions, including cardiovascular issues, are preventable, or at least more controllable when warning signs are detected.

The economic factors of racism decrease the probability of prevention. Because wages are lower, doctor visits are infrequent. Many low paying jobs do not include health benefits. Workers may also resist relinquishing a day's pay to go to a doctor's office for a checkup, as well.

Availability and procedural disparities

The there is also a fracture quality of health care for minorities once a diagnosis is made and treatment is prescribed. The impact of this is obvious in all age groups. Infant mortality rates are higher and life expectancy is shorter in minority communities. In one example of specific treatment recommendations, the Journal of the American Society of Nephrology cites a study that revealed that 35% fewer minority patients who were eligible for kidney transplants received them, versus the non-minority eligible patients.

Steps the medical community must take

Addressing social risk factors among minorities, diversifying the health care work force, improving the availability of health care and providing more avenues to primary care are among the strategies that can help.

There are programs in place that provide outreach into minority and underprivileged communities to provide better health care. Medical institutions should encourage their doctors and nurses to participate in programs that deal with childhood intervention, senior care and assistance to the disabled.

The American Medical Association has acknowledged that bias exists within health systems and peripheral institutions that contribute to the disparities. Health professionals and institutions are being urged to examine and correct it.

Ask Dr. Haqqani

If you have questions about your cardiovascular health, including heart, blood pressure, stroke lifestyle and other issues, we want to answer them. Please submit your questions to Dr. Haqqani by e-mail at questions@vascularhealthclinics.org.

Dr. Omar P. Haqqani is the chief of Vascular and Endovascular Surgery at Vascular Health Clinics in Midland: http://www.vascularhealthclinics.org

Read the original here:
Dr. Haqqani: Eliminating disparity in health care - Midland Daily News

As record breaking numbers continue in Georgia, health officials weigh in on what it means.

ATLANTA It was another record-breaking day for new COVID-19 cases in Georgia. Wednesday, the Department of Public Health reported 2,946 new cases.

The number of current COVID-19-related hospital patients now stands at 1,570, as shown in the graphic below. Thats not the highest number of active patients weve had in this pandemic, but it is the largest since Georgia Emergency Management started providing the data on May first.

I think were seeing a diagnosis made earlier in the course of disease than we did in March or April, and thats because of increased access to testing, said Dr. Danny Branstetter, who serves as the Medical Director of Wellstars Infection Prevention.

Wellstar Kennestone sits in Health District N, which, according to Georgia Emergency Management, is already using 89 percent of its ICU beds between COVID-19 and other illnesses.

Im really concerned about what the next week holds as far as the demand on our ICU level care," Branstetter said.

The line on the chart above indicates the number of active COVID-19 patients since May.

Branstetter said hospitals are ready for it and have room to care for patients, despite how that GEMA data might sound.

We probably operate on a normal basis, without COVID, at a little bit higher than that at capacity. So, those numbers are not too concerning, Branstetter added. "If anything, it says, 'yes, weve got room to take care of people.' And remember, that number does not include our surge capacity planning."

What is making Branstetter concerned, is the unnecessary risk too many are taking by not wearing masks or social distancing.

All of these infections are preventable if we just continue to push on and persist. I know everyones got COVID fatigue. I have COVID fatigue. Its important though we get up every day and realize we still have to do our part. We still have to get up and do all those things we really dont enjoy," Branstetter said.

Hes especially concerned about the rise in cases among 18 to 29 year olds. They now account for 22 percent of the state's positive cases, as shown in the graphic below.

Thats concerning a little bit because theyre the most mobile members of society, so theyre likely to bring it places, Branstetter explained. The one thing I want that age group particularly to know, theyre not immune to the complications of COVID infections.

Thats because young adults tend to visit doctors less for preventative medicine, so they dont know if they have any of the underlying factors that increase risk. He said now that theyre coming in, doctors are seeing an increase in high blood pressure and diabetes diagnosis.

Piedmont Health System shared a chart with us, based on internal surveys regarding patient care. It seems people were just starting to feel comfortable with the idea of going back to the hospital for treatment of chronic illnesses and elective surgeries until mid-June.

Despite a dip in confidence, both Piedmont and Wellstar say theyre well-equipped to handle patients of any kind and urged those in need of care not to wait.

Dont delay. Were very prepared to separate those with COVID infection or potential infection from everyone else, so its very safe to come to receive your health care," Branstetter said.

11Alive is focusing our news coverage on the facts and not the fear around the virus. We want to keep you informed about the latest developments while ensuring that we deliver confirmed, factual information.

We will track the most important coronavirus elements relating to Georgiaon this page.Refresh often for new information.

OTHER HEADLINES:

Excerpt from:
Here's what is - and isn't -concerning to health experts watching coronavirus in Georgia - 11Alive.com WXIA

GLOBAL

However, such mobile phone apps have raised data privacy and bioethical issues around their use in public health.

Public health relies on good quality surveillance, noted Angus Dawson, professor of bioethics and director of Sydney Health Ethics at the University of Sydney, Australia.

However, contact tracing can generate all kinds of ethical problems, he said, speaking at a June webinar organised by the bioethics group of the Association of Pacific Rim Universities (APRU) Global Health Program, noting that it raises issues of privacy, informed consent and confidentially.

One of the concerns is what actually is the data being collected, said Dawson. How much of it is identifiable data in relation to particular individuals?

It is not just a technical issue but a medical one too, he said, adding that every intervention in the COVID area has to involve ethical considerations whether we are talking about distribution of protective equipment, ICU beds, or hopefully in the future when we might have some vaccines.

Apps in use in the region include the Alipay Health Code app in China, which codes people as green or red depending on their health status and requires identity card details as well as full face scans.

Hong Kong has the StayHomeSafe app combined with a wristband linked with the app. Developed by Gary Chan, a professor at Hong Kong University of Science and Technology, the app maps a unique footprint of a persons locality. Stepping out beyond certain perimeters triggers an alert. Taiwans Intelligent Electronic Fences System app uses different measures, but with similar functionality.

New Zealands NZ COVID Tracer app is based on a digital diary of places visited by individuals by scanning the official QR codes, which can alert and be shared with contact tracers.

Singapores TraceTogether app, developed by the Government Technology Agency together with the Ministry of Health, exchanges short-distance Bluetooth signals between mobile phones to detect other TraceTogether users in close proximity. The data is shared once the individual is contacted by contact tracers. The Singaporean app has also been adopted in Japan and Australia.

Some of the apps have supplementary functions where individuals can input symptoms to create an alert.

What happens to the data?

Calvin Ho, associate professor in the faculty of law at the University of Hong Kong researching health and biomedical technologies, said international health regulations drawn up by the World Health Organization (WHO) put a lot of emphasis on technological surveillance as well as rapid technological advances, but it did not quite anticipate the developments that have arisen from this particular [coronavirus] outbreak.

In many of the countries and cities where mobile phone use is high, such apps have been very effective in controlling the rate of infections many of the cities did not have to introduce a complete lockdown, Ho said during the webinar.

However, privacy is a huge question. We do not yet know what is going to happen to the data, Ho said. There needs to be public discussion on what principles of data protection have to be observed.

For the public to be willing to take part, trust and transparency is crucial, he added.

In the midst of an outbreak, as we have seen in South Korea, for example, people are very conscious about social responsibility. Theres a very strong societal and peer emphasis so people tend not to invoke their right [to privacy] straight away. That seems to be the phenomena right across East Asia, he said. But also in Australia and New Zealand, people were extremely cooperative.

In Western Europe and the United States, people have been more vocal on privacy issues.

Privacy has not been highlighted as a huge issue across Asia, particularly in the initial stages, Ho said. But it does not mean these concerns are not there. Individuals remain concerned about whats going to be used out of all the data thats been collected about them. Its very vivid in their minds.

Involvement of tech giants

Ho described the use of such mobile technologies as a form of mass surveillance. Some ethical principles are not always followed with surveillance, he noted.

The WHO Guidelines on Ethical Issues in Public Health Surveillance, published in 2017, state: Those responsible for surveillance should identify, evaluate, minimise and disclose risks for harm before surveillance is conducted. Monitoring for harm should be continuous, and, when any is identified, appropriate action should be taken to mitigate it.

Ho, who helped draft the WHO guidelines, noted that they were drawn up with governments and public health systems in mind, rather than corporations or NGOs.

Ho pointed to the involvement of technology giants such as Google and Apple in developing some of the apps in use during the pandemic, which raises questions of whether we are further empowering very powerful industry players with control over public health measures, and added that it is unclear what such companies will do with the data.

Technically, the data will be owned by these commercial developers. With other contact-tracing apps there should be an agreement with the public at the authority and then the data belongs to the public health authority, Ho told University World News.

Ho added that if such companies are not carefully monitored, then ultimately it does mean that these huge commercial entities could potentially exploit public health systems and potentially vulnerable individuals, essentially for political gains or some kind of influence over government.

Balance of public health and privacy

Dawson, who is also one of the drafters of the WHO guidelines, said COVID needs to be thought about as a global ethical issue, and not just a concern to an individual.

Issues of data ethics and the balance of personal privacy often come down to the advantages we might have through having that data, Dawson said. Public health systems can have very good reasons to try to understand what the levels of infection are in different regions and cities across the world and then use that to plan how they are going to respond.

He noted that with some of the recent contact-tracing apps, some of that data is identifiable and some is not.

We should not just think public good versus privacy. There are ways to try to think about how they are both important and we can put protections in place, for example putting coding attached to individual level data to make sure individuals cant be identified, Dawson said.

Research ethics

Bioethical principles used in conducting medical research can be useful in guiding use and data issues surrounding such apps.

This kind of surveillance is very similar to research in many ways, said Ho. It can involve similar methodologies and activities. These can include systematic investigation, medical record review and data mining.

Both involve human subjects and both can raise similar ethical issues, including exposure of subjects to risk, standards of care and questions about informed consent. However, Ho pointed out: Informed consent is a basic tenet of research ethics, but it is often not sought in the context of surveillance.

Biomedical research has strong regulations in place and systems overseen by ethical committees in universities, hospitals and research institutions.

There is less institutional oversight for surveillance, which means app-based surveillance, data and research derived from it may not undergo ethics committee reviews, Ho said.

With academics and researchers well trained and experienced with research ethics, they can contribute to improving bioethical aspects of surveillance, Ho said, adding that university input into issues of data governance, accountability and transparency measures were likely in the wake of the pandemic.

Mellissa Withers, associate professor at the department of preventive medicine at the University of Southern California in the US and director of the APRU Global Health Program, said the bioethics group within the APRU programme would continue to look at such issues to inform policy-makers.

A lot of the experts are involved in research ethics committees, and they are very active in reviewing the ethics of human subject research in their own universities, but more needs to be done across universities and, in particular, there is a real need for sharing and doing training in low- and middle-income countries, she noted.

There was a lot of interest from [those in] the Philippines and Indonesia attending the webinar which shows they really want some guidelines and recommendations on bioethics. They are interested in building capacity around these areas and learning whats going on in the field.

Structured regulation needs to be in place or at least these ethical issues need to be considered because there is the opportunity for [data] misuse by governments, Withers told University World News.

We need more standardised policies that can be implemented across countries because it wont go away even after COVID-19. The amount of data collected for public health purposes is growing exponentially every year.

More here:
COVID-19 apps Are there enough ethical safeguards? - University World News

By: Reuters | Geneva, London | Published: July 4, 2020 6:39:32 am There is no proven vaccine against the disease now, while 18 potential candidates are being tested on humans.

The World Health Organization (WHO) should soon get results from clinical trials it is conducting of drugs that might be effective in treating COVID-19 patients, its Director General Tedros Adhanom Ghebreyesus said on Friday.

Nearly 5,500 patients in 39 countries have so far been recruited into the Solidarity trial, he told a news briefing, referring to clinical studies the U.N. agency is conducting.We expect interim results within the next two weeks.

The Solidarity Trial started out in five parts looking at possible treatment approaches to COVID-19: standard care; remdesivir; the anti-malaria drug touted by U.S. President Donald Trump, hydroxychloroquine; the HIV drugs lopinavir/ritonavir; and lopanivir/ritonavir combined with interferon.

Earlier this month, it stopped the arm testing hydroxychloroquine, after studies indicated it showed no benefit in those who have the disease, but more work is still needed to see whether it may be effective as a preventative medicine.

Mike Ryan, head of the WHOs emergencies programme, said it would be unwise to predict when a vaccine could be ready against COVID-19, the respiratory disease caused by the novel coronavirus that has killed more than half a million people.

While a vaccine candidate might show its effectiveness by years end, the question was how soon it could be mass produced, he told the U.N. journalists association ACANU in Geneva.

There is no proven vaccine against the disease now, while 18 potential candidates are being tested on humans.

WHO officials defended their response to the virus that emerged in China last year, saying they had been driven by the science as it developed. Ryan said what he regretted was that global supply chains had broken, depriving medical staff of protective equipment.

I regret that there wasnt fair, accessible access to COVID tools. I regret that some countries had more than others, and I regret that front-line workers died because of (that), he said.

He urged countries to get on with identifying new clusters of cases, tracking down infected people and isolating them to help break the transmission chain.

People who sit around coffee tables and speculate and talk (about transmission) dont achieve anything. People who go after the virus achieve things, he said.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest World News, download Indian Express App.

Go here to read the rest:
WHO sees first results from coronavirus drug trials within two weeks - The Indian Express

Editors note: The Salt Lake Tribune is providing free access to critical stories about the coronavirus. Sign up for our Top Stories newsletter, sent to your inbox every weekday morning. To support journalism like this, please donate or become a subscriber.

The state recorded another 499 confirmed cases of COVID-19, the Utah Department of Health announced Wednesday with one more Utahn dying from the disease.

A Salt Lake County man, between ages 65 and 84 and in a hospital, was the latest person in Utah to die from COVID-19, UDOH reported. His death brings the states toll due to the coronavirus to 173 people.

Another 32 people were hospitalized with COVID-19, according to the state report. There were 194 people hospitalized in Utah as of Tuesday (hospitalization figures are a day behind case counts), and there have been 1,476 Utahns hospitalized with COVID-19 since the first cases were reported in March.

Wednesdays new cases bring the states total number of cases to 22,716. Of those, 12,707 are considered recovered meaning, by the states definition, its been three weeks since they were diagnosed and theyre still alive.

Another 2,605 tests were administered Wednesday, bringing the total number of Utahns tested to 343,358. The rate of positive tests for the last seven days is 11.8%, and its at 6.6% since the first cases were reported in March.

The state has averaged 561.7 cases per day in the last week. Thats well above the 200-cases-per-day average the states epidemiologist, Dr. Angela Dunn, said in an internal memo last month would be necessary by July 1 for the state to avoid a complete shutdown of the states economy.

Also Wednesday, researchers at the University of Utah announced the latest results from the Utah HERO study, measuring the spread of COVID-19 in Utah.

Counting nearly 9,000 residents in Davis, Salt Lake, Summit and Utah counties, the studys first phase found about 1% tested positive for COVID-19 antibodies. The results match the preliminarily findings, announced Friday in a webinar.

Antibody tests are a lagging indicator, showing more of where the virus has been than where its going, said Dr. Stephen Alder, the Utah HERO studys director of field operations and a professor in the U.s Department of Family and Preventative Medicine.

Were looking a few weeks in the past, when were looking at antibodies, Alder said. Its a good historical marker.

The second wave of the study will expand past the four counties measured in the first phase, into hot spots of viral activity that were going to go into and understand those areas better, Alder said.

Originally posted here:
Utah tallies another 499 cases of COVID-19, and one more death - Salt Lake Tribune

In this moment of social distancing and turmoil, many of us are yearning for the collective inspiration and joy that is unique to the concert experience. In a special Power of Live section that appears in our new issue, a number of singular voices chime in with their thoughts on the importance of in-person gatherings.

Were multidimensional rhythm machines embedded in the universe of rhythmits as simple as that, observes Mickey Hart. The species needs music, it needs sound, it needs rhythm. Were coded for it. We dont have much choice since were made up of rhythms ourselves. His remarks reflect a lifetime of experiencesfrom his years with the Grateful Dead to his current role in Dead & Company and his pioneering world-music pursuits. Hart has also explored the topic in his books Drumming at the Edge of Magic, Planet Drum and Spirit Into Sound, as well as through his scientific research into the impact of rhythm on diseased and damaged brains.

During this moment of quarantine, some people have described a physical longing for live music. Whats your response to that?

Many people dont appreciate the power of music. When its ripped away, all of a sudden, you start to think, Wow, whats missing in my life? Thats the thing about music: It allows people to engage in life.

Remember, were a vibratory animal. The big bang was the inspiration for the whole universe 13.8 billion years ago and its the glue. So, youre made up of star stuff as they say, and that sets your brain. Your brain is the master clock; thats what music is. So its the cognitive part of you that you are missing. It defines our species. Its not a pleasure; its a necessity.

Music is just controlled vibrationsand the universe started through vibrations. Thats a lot to take away from people. Its one of the greatest ingredients in this thing we call life. Without music, the human race would be in a lot worse of a place. I see life in rhythmic terms because Im a rhythmist primarily. Life is filled with rhythms: good rhythms and bad rhythms. A bad rhythm is stepping in front of a car; a good rhythm is having a happy life or a healthy life. When youre out of rhythm, youre not as healthy and things arent as efficient.

Theres also that community aspect, which youve experienced over the years.

Were groupists. Humans like to group; were more powerful in groups. So take away music, and youre not just taking away the sound, youre taking away everything that goes around the music too. We dance with life, and thats partly why we go to concerts. Music allows us to dance, which is really important these days.

The other thing about music is that it brings you into the now, into the moment not the past, not the future, but the now. Thats also something that youll really miss when its yanked away. When youre in the sphere of music, those cares go away, at least for the time that the music is playing.

Playing live is important. For me, its more than importantits necessary. Playing in the studio is one thing, but when you play with an audience, not to an audience, thats a whole different ball of wax. Playing live in front of people is just so energizing for both the audience and for the band. It serves a great purpose in civilization.

Can you talk about the impact of music on the mind?

The brain is a rhythm machine. There are billions of electrical signals going on in the brain at any given nanosecond. Its the most extraordinary instrument and tool that we know on the planet. Life is really all about cognition, about how things are recognized and how we react to them. Thats what music is all about: neurologic function. You see these gamma waves and beta waves associated with certain states of mind. Consciousness comes out of gamma waves and music is full of gamma waves. Whats being studied now is neurologic functionmusic in the mind, music in the brain, how you can use it for preventative medicine. Thats being examined by people like Adam Gazzaley, a neuroscientist at UCSF, and Nina Kraus at Northwestern.

I sit here making drones every day. I wake up every day and my meditation is musical, so I drone. I meditate and drone and try to create these positive wave forms. We even have a little group on Zoom and we find time each week to work on drones. These drones are deep and low so they affect these brain waves. On the low-end, below 40 or 50 hertz, is where you find the gamma, which is very valuable. Everybody is looking at what the beta and gamma do how to reach them and how to perform with them. Its like a dance.

Music feeds the brain; youve gotta mind your head and, if you dont, youll fall into disrepair. A happy brain is a good brain and thats a really important thing to remember.

You mentioned that playing live is important to you. What are you doing in lieu of a Dead & Company tour?

I play every day for at least three hours, even on Sundays, to stay in the game. You lose your skills after you dont practice for a long time, no matter who you are. So Im hoping that were all keeping our skills up until the day we can actually go out and play. Can you imagine what its like practicing for 70 years and then being told that you cant go out and play?

Can you imagine all the work that musicians put into their art and then, all of a sudden, thats ripped away? Theres an enormous vacancy there.

Being a musician is really a hard life and most are struggling. Right now, its hitting our community tremendously. There are a few of us who are luckyweve been practicing the art for years and years. For the youngsters who are coming up, its really difficult. But you have to stay at it all the time. You cant just sit back and drink a beer and watch TV or whatever. Youve got to be at it constantly or else itll slip away.

I see life in terms of rhythm and its not just about music. But you can look at life as a musical instrument as wellhow you play it is how you look at life. Music is a really important part of this developing species. Its part of our DNA. Musicians are coded to make music; they make it because thats really who they are.

Now, we are developing a whole new way to transmit this energy. The music thats going to come out of this is going to be revealing. I cant wait to hear what artists are doing now. Theyre writing, theyre composing, theyre practicing. I think that this will bring more light than darkness when its overand it will be over. Then we can get back to making the world a better place because thats what music certainly does. It doesnt make it worse; it makes it a lot better. Were going to make it the best we can because thats what musicians do.

View post:
Mickey Hart on the Power of Live - Relix

Geneva/London The World Health Organization has updated its account of the early stages of the COVID-19 crisis to say it was alerted by its own office in China, and not by China itself, to the first pneumonia cases in Wuhan.

The U.N. health body has been accused by U.S. President Donald Trump of failing to provide the information needed to stem the pandemic and of being complacent towards Beijing, charges it denies.

On April 9, WHO published an initial timeline of its communications, partly in response to criticism of its early response to the outbreak that has now claimed more than 521,000 lives worldwide.

In that chronology, WHO had said only that the Wuhan municipal health commission in the province of Hubei had on Dec. 31 reported cases of pneumonia. The U.N. health agency did not, however, specify who had notified it.

WHO chief Tedros Adhanom Ghebreyesus told a news conference on April 20 that the first report had come from China, without specifying whether the report had been sent by Chinese authorities or another source.

But a new chronology, published this week by the Geneva-based institution, offers a more detailed version of events.

It indicates that it was the WHO office in China that on Dec. 31 notified its regional point of contact of a case of viral pneumonia after having found a declaration for the media on a Wuhan health commission website on the issue.

The same day, WHOs epidemic information service picked up another news report transmitted by the international epidemiological surveillance network ProMed based in the United States about the same group of cases of pneumonia from unknown causes in Wuhan.

After which, WHO asked the Chinese authorities on two occasions, on Jan. 1 and Jan. 2, for information about these cases, which they provided on Jan. 3.

WHO emergencies director Michael Ryan told a news conference Friday that countries have 24-48 hours to officially verify an event and provide the agency with additional information about the nature or cause of an event.

Ryan added that the Chinese authorities immediately contacted the WHO as soon as the agency asked to verify the report.

WHO chief Tedros Adhanom Ghebreyesus told a news briefing that the organization should soon get results from clinical trials it is conducting of drugs that might be effective in treating COVID-19 patients. | AFP-JIJI

Trump has announced that his country, the main financial contributor to WHO, will cut its bridges with the institution, which he accuses of being too close to China and of having poorly managed the pandemic.

The WHO denies any complacency toward China.

Also Friday, Tedros told a news briefing that the WHO should soon get results from clinical trials it is conducting of drugs that might be effective in treating COVID-19 patients.

Nearly 5,500 patients in 39 countries have so far been recruited into the Solidarity trial, he said, referring to clinical studies the U.N. agency is conducting.

We expect interim results within the next two weeks.

The Solidarity Trial started out in five parts looking at possible treatment approaches to COVID-19: standard care; remdesivir; the anti-malaria drug touted by Trump, hydroxychloroquine; the HIV drugs lopinavir/ritonavir; and lopanivir/ritonavir combined with interferon.

Earlier this month, it stopped the arm testing hydroxychloroquine, after studies indicated it showed no benefit in those who have the disease, but more work is still needed to see whether it may be effective as a preventative medicine.

Ryan, the WHOs emergencies program chief, said it would be unwise to predict when a vaccine could be ready against COVID-19, the respiratory disease caused by the novel coronavirus that has killed more than half a million people.

While a vaccine candidate might show its effectiveness by years end, the question was how soon it could be mass produced, he told the U.N. journalists association ACANU in Geneva.

There is no proven vaccine against the disease now, while 18 potential candidates are being tested on humans.

WHO officials defended their response to the virus that emerged in China last year, saying they had been driven by the science as it developed. Ryan said what he regretted was that global supply chains had broken, depriving medical staff of protective equipment.

WHO emergencies director Michael Ryan | Pool via REUTERS

I regret that there wasnt fair, accessible access to COVID tools. I regret that some countries had more than others, and I regret that front-line workers died because of (that), he said.

He urged countries to get on with identifying new clusters of cases, tracking down infected people and isolating them to help break the transmission chain.

People who sit around coffee tables and speculate and talk (about transmission) dont achieve anything. People who go after the virus achieve things, he said.

On the sidelines ACANU briefing, another top WHO official said almost 30 percent of genome sequencing data from samples of the COVID-19 virus collected by the body have shown signs of mutation, but there is no evidence this has led to more severe disease.

I think its quite widespread, said Soumya Swaminathan, WHO chief scientist.

The U.N. agency has so far collected 60,000 samples of the disease, she said.

Scientists at Scripps Research this month found that by April the mutated virus accounted for some 65 percent of cases submitted from around the world to a major database.

The genetic mutation in the new coronavirus, designated D614G, significantly increases its ability to infect cells and may explain why outbreaks in northern Italy and New York were larger than ones seen earlier in the pandemic, they found in a study.

Maria Van Kerkhove, technical lead on the COVID-19 pandemic at the WHO, said at Fridays briefing the mutated strain had been identified as early as February and had been circulating in Europe and the Americas.

So far, there is no evidence it leads to more severe disease, she said.

Go here to read the rest:
WHO says it was first alerted to coronavirus by its office, not China - The Japan Times

As Canada continues to reopen, some grocery stores, salons and other businesses have implemented temperature screening an approach that uses a touchless scanner to measure a persons body temperature in an attempt to prevent the spread of the novel coronavirus.

The process was made mandatory for all air travellers in Canada in mid-June. Any passenger who shows a fever on two measurements, taken 10 minutes apart, will be asked to rebook after 14 days.

However, some experts wonder whether the step is effective given a person can shed the COVID-19 virus without having a fever or any change in body temperature. The tool often used to measure temperature has also been shown to be unreliable.

READ MORE: Temperature screening not always reliable to mitigate coronavirus risk, experts say

For those reasons, temperature screening has not been recommended by Canadas chief public health officer Theresa Tam. In fact, she quickly shut down the approach when more businesses began implementing the practice in May.

The more you actually understand this virus, the more you begin to know that temperature-taking is not effective at all, Tam said in a ministerial update that month.

Tam said the likelihood of screening someone who was symptomatic was relatively inefficient in comparison to those who were asymptomatic.

If we have a significant number of asymptomatic or pre-symptomatic people, that also even reduces the effectiveness even more.

Dr. Susy Hota, the medical director of the Infection Prevention and Control and Medical Device Reprocessing department at the University Health Network in Toronto, agrees.

There really are a lot of limitations to temperature checks, and Im not really convinced that theyre worth investing in for this purpose, Hota said.

READ MORE: Canada to screen air travellers for fever amid coronavirus pandemic: Trudeau

There are also inaccuracies with the temperature probes used for this purpose, Hota said.

She worries they can give patrons and business owners a false sense of security.

Temperature screening is typically not an effective way to detect COVID-19 when used on its own, and thats because of the way the virus spreads.

When we talk about the issue of pre-symptomatic shedding and transmission, were talking about people who have no symptoms yet so no fever, Hota said.

Once youve developed the fever, we know what were dealing with but in the pre-symptomatic phase, a temperature check wont help.

Problems can also arise from the touch-less temperature probes currently being used in airports, grocery stores and by other businesses.

Its a variable that isnt infallible, said Dr. Leighanne Parkes, infectious disease specialist and microbiologist at the Jewish General Hospital in Montreal.

It depends on the instrument that were using, the ambient temperature, (if) the instrument is calibrated correctly, is the individual coming in from a hot outside or a cold outside?

All these things come into play when a temperature probe is used, making true measures hard to come by.

READ MORE: You might be wearing your mask, gloves wrong. How to use PPE properly

There are also other reasons a persons body temperature could be elevated that dont have to do with COVID-19.

Medication, certain pre-existing conditions, weather and what you were doing immediately prior to having your temperature checked are all factors that can affect your body temperature, Hota said.

It is possible that your ambient temperature and what you were doing before might register a higher temperature than you really would have otherwise, she said.

However, Parkes believes temperature screening could be helpful when its bundled with other preventative health measures.

If you have an adequately calibrated machine, youre indoors using appropriate techniques and youre also symptom-screening for things that are not fever, and risk factors including contact, those altogether can pick up some of the most high-risk cases, Parkes said.

Temperature screening should be considered just one layer in a pyramid of prevention, she said.

Its not a replacement for the other means that we have in place, such as social distancing, masking in public spaces, adequate ventilation, adequate environmental cleaning all those things combined.

Although temperature screening may not accurately detect COVID-19, its still within the rights of a business to deny you service on the grounds of a high temperature.

This is because employers and employees have the right to a safe working environment.

You cant be denied entry on grounds of race or religion because thats discrimination, but if your temperature is above some arbitrary scale, then you can be denied entry, said Bernard Dickens, professor emeritus of health law and policy in the faculty of law, faculty of medicine and Joint Centre for Bioethics at the University of Toronto.

READ MORE:Planes, salons and grocery stores: Companies that require masks in Canada

Its a security ground to protect the staff who work in the facility. They have a right to a safe working environment, and the store is responsible for the safety of its employees.

Basically, any business can make conditions for who they serve as long as they dont discriminate in violation of the human rights code.

For this reason, you can refuse to take a temperature test, but the store can refuse your entry upon doing so.

You have no right to go into the store because the store can set reasonable conditions , Dickens said.

Questions about COVID-19? Here are some things you need to know:

Symptoms can include fever, cough and difficulty breathing very similar to a cold or flu. Some people can develop a more severe illness. People most at risk of this include older adults and people with severe chronic medical conditions like heart, lung or kidney disease. If you develop symptoms, contact public health authorities.

To prevent the virus from spreading, experts recommend frequent handwashing and coughing into your sleeve. They also recommend minimizing contact with others, staying home as much as possible and maintaining a distance of two metres from other people if you go out.

In situations where you cant keep a safe distance from others, public health officials recommend the use of a non-medical face mask or covering to prevent spreading the respiratory droplets that can carry the virus.

For full COVID-19 coverage from Global News, click here.

With files from Global News Emerald Bensadoun

Meghan.Collie@globalnews.ca

2020Global News, a division of Corus Entertainment Inc.

See the original post here:
Can I refuse a temperature check? What to know about the COVID-19 screening tool - cjoy.com

Camel milk is converted into powder form to preserve it for a longer time period. Camel milk powder has high levels of iron, protein, and vitamin C, and less fat. Apart from being rich in nutrients, camel milk powder is used as a potential preventative medicine for diabetes. According to the studies conducted by some researchers in Bikaner, Rajasthan, camel milk has sufficient levels of insulin, which can help prevent and even treat type 1 and type 2 diabetes. Camel milk powder helps in providing immunity due to its high levels of proteins and other organic compounds. Since many of these compounds have antimicrobial properties, the consumption of camel milk can improve human health by boosting the immune system.

Request Sample Copy of Camel Milk Powder Market: https://www.premiummarketinsights.com/sample/TIP00028161

Key Players:

After studying key companies, the report focuses on the startups contributing towards the growth of the market. Possible mergers and acquisitions among the startups and key organizations are identified by the reports authors in the study. Most companies in the Camel Milk Powder market are currently engaged in adopting new technologies, strategies, product developments, expansions, and long-term contracts to maintain their dominance in the global market.

Analysis tools such as SWOT analysis and Porters five force model have been inculcated in order to present a perfect in-depth knowledge about Camel Milk Powder market. Ample graphs, tables, charts are added to help have an accurate understanding of this market. The Camel Milk Powder market is also been analyzed in terms of value chain analysis and regulatory analysis.

Avail Discount on this [emailprotected]: https://www.premiummarketinsights.com/discount/TIP00028161

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Risk Assessment for Investing in Global Market

Critical Success Factors (CSFs)

The competitive landscape of the market has been examined on the basis of market share analysis of key players. Detailed market data about these factors is estimated to help vendors take strategic decisions that can strengthen their positions in the market and lead to more effective and larger stake in the global Camel Milk Powder market. Pricing and cost teardown analysis for products and service offerings of key players has also been undertaken for the study.

Table of Contents:

1 Executive Summary

2 Preface

3 Camel Milk Powder Market Overview

4 Market Trend Analysis

5 Global Camel Milk Powder Market Segmentation

6 Market Effect Factors Analysis

7 Market Competition by Manufacturers

8 Key Developments

9 Company Profiling

About Premium market insights:

Premiummarketinsights.comis a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Sameer Joshi Call: US: +1-646-491-9876, Apac: +912067274191Email: [emailprotected]

Follow this link:
Camel Milk Powder Market 2027 COVID-19 Impact and Global Analysis by Type (Full Cream Milk Powder, Skimmed Milk Powder); Application (Infant formula,...

Goldman Pharmaceutical Group announces the creation of the only FDA registered over-the-counter pet medicines available online and without a prescription, Pet OTC. Treating animals suffering from motion sickness, digestive issues and emotional distress.

NEW YORK, July 7, 2020 /PRNewswire/ -- Goldman Pharmaceutical Group announces that its full lineup of over-the-counter pet medications include: NausX, an anti-emetic medication designed for dogs with motion sickness which include nausea, dizziness and vomiting; Calmatrol, an anti-histamine medication designed to relieve dogs in stress related circumstances bringing instant relief to your dog; and DIFIXN, an anti-diarrheal treatment designed to relieve dogs with diarrhea.

American Pet Products Association (APPA) announced in February of this year that the U.S. is expected to reach a record 100 billion in sales for pet products and services. The CEO, Steve King of the American Pet Products Association (APPA), reported that U.S. sales of pet products and services are nearing $100 billion for the first time, as 2019 spending reached $95.7 billion. The announcement came during Global Pet Expo, the largest annual pet products trade show presented by APPA and the Pet Industry Distributors Association (PIDA). APPA's pet industry expenditures encompass spending in four major categories: Pet Food & Treats; Supplies, Live Animals & OTC (over-the-counter) Medicine; Vet Care & Product Sales; and Other Services.

"Scientific research from the Human Animal Bond Research Institute (HABRI) shows that when you invest in your pets' health, you're investing in your own health," said King. "Improved physical health and reduced feelings of loneliness and social isolation are just a few of the health benefits you're likely to experience by owning a pet."

Goldman Pharmaceutical Group understands that motion sickness in dogs is a common problem before you know it, your furry best friend's breakfast can end up all over your backseat!

NausX by Pet OTC is the ultimate treatment for canine motion sickness. It's a powerful preventative when taken before a trip, and a fast-acting remedy to treat sudden symptoms immediately. Some of the signs and symptoms of motion sickness in dogs include:

Goldman Pharmaceutical Group created Calmatrol as a calming formula that reduces anxiety and stress in dogs and puppies for a much more confident and relaxed pet. Calmatrol by Pet OTC will soothe anxious dogs and alleviate symptoms of:

The Calmatrol treatment by Pet OTC is formulated to encourage canine calmness android behavior, while helping your fury friend overcome feelings of nervousness, agitation and aggression.

The last of the over-the-counter pet treatments manufactured by Goldman Pharmaceutical Group is Difixn by Pet OTC an anti-diarrheal treatment that works fast to relieve dogs of the symptoms of Diarrhea.

Pet OTC Products:

Associated Press American Pet Products Association (APPA) press release cited, visit https://apnews.com/4b4705fc9bc1cdd6f3f951af2d3cd63d for more information.

About American Pet Products Association (APPA)

The American Pet Products Association is the leading trade association serving the interests of the pet products industry since 1958. APPA membership includes more than 1,100 pet product manufacturers, their representatives, importers and livestock suppliers representing both large corporations and growing business enterprises. APPA's mission is to promote, develop and advance pet ownership and the pet product industry and to provide the services necessary to help its members prosper. APPA is also proud to grow and support the industry through the following initiatives: Pets Add Life (PAL), Tony La Russa's Animal Rescue Foundation (ARF) Pets and Vets Program, the Human Animal Bond Research Institute (HABRI), the Pet Industry Joint Advisory Council (PIJAC), Bird Enjoyment and Advantage Koalition (BEAK), and the Pet Care Trust. Visit http://www.americanpetproducts.org for more information.

About Goldman Pharmaceutical Group (GPG)

Goldman Pharmaceutical Group is concerned with the overall health and well being of people and animals. GPG develops and markets products dedicated to human and animal health and safety. The company markets disinfectants, diagnostic test kits to detect viral bacteria, allergens, teeth and oral care, fungal nail treatments, acne skincare, luggage technology, pet food, pet wellness aids, and over-the-counter pet treatments. Goldman Pharmaceutical Group is a leader in contract manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, wound care and disinfectants.

GPG started as a pharmaceutical repacking company focusing mainly on private labeling. Their mission is to continuously innovate and bring new products to market within the medical and pharmaceutical industries, while upholding and creating strong relationships with their clientele and the public. Visit http://goldmanpharma.com/ for more information. Exclusive Manufacturer and Distributor for Pet OTC Products.

Contact Information for Goldman Pharmaceutical Group and Pet OTC:Jeff Magsitzajeff@goldmanpharma.comwww.petsotc.com

Media Contact:Annamarie Seabright, PublicistSignature |PRA Public Relations & Digital Marketing Agency in California and New Yorkannamarie@SignaturePR.presswww.SignaturePR.press

View original content to download multimedia:http://www.prnewswire.com/news-releases/us-pet-products-and-services-are-expected-to-reach-100-billion-in-sales-for-2020-the-over-the-counter-pet-meds-are-a-huge-percentage-of-consumer-spending-301088845.html

SOURCE Goldman Pharmaceutical Group

View post:
US Pet Products and Services are Expected to Reach 100 Billion in Sales for 2020, the Over-the-Counter Pet Meds are a Huge Percentage of Consumer...

Genetic engineering. Fermentation. Virology. Put on your safety goggles youre about to earn one of the best Biotechnology degrees in the nation.

Biotechnology is all about using biological systems plants, animals, genes, etc. to develop or design new products. This covers a lot of ground. You could use biotechnology in medicine, agriculture, food science, industrial materials the list could go on!

If you want to use science to fight diseases, solve hunger crises, and develop new biofuels, then a degree in Biotechnology is right up your alley.

The first step to a career in this area is a bachelors degree in either biology or biotechnology.

Youll find that biotechnology covers a lot of different areas. Most of these schools help guide you into a facet of biotechnology that best fits your interests and academic passions.

For example, do you want to get down to the nitty-gritty of the natural world? Check out the Microbial Biotechnology concentrations at UC Davis, Cal Poly Pomona, or SUNY College of Environmental Science and Forestry.

Do you like looking at the bigger picture? Then take a look at the Plant Biotechnology and Animal Biotechnology tracks at the University of Georgia and SUNY Cobleskill.

Regardless of which specific area of biotechnology you want to explore, all of these programs will give you a fantastic foundational understanding of the basics. If your schedule isnt quite going to line up with a full-time, on-campus program, check out College Choices list of the 50 Best Online Colleges and Universities.

Earning a degree in the world of biotechnology will guarantee you not only a rewarding career, but a financially secure future. You could take this degree in so many different areas, but three potential roles you could find yourself pursuing are a Microbiologist, a Biomedical Engineer, or a Biological Technician. All three of these jobs offer a comfortable annual salary:

These figures, of course, adjust depending on where you are working. For example, working in the pharmaceutical and medical world will earn you a higher salary than working at a private or state-level setting. According to the Bureau of Labor and Statistics, employment in biotechnology careers is expected to increase by over 10 percent in the next 10 years.

Biotechnology is a field with virtually no limits. You can take your degree and apply it to medicine, agriculture, transportation, and beyond. If youre more interested in the research side of things, you could work in a laboratory or a think-tank at a university.

If youre the kind of person who likes to get their hands dirty, you could cater your career to field experiments and trips around the world to test soil and plant samples. Here are just a few of the many careers you could pursue with a degree in biotechnology:

Since youre starting with a bachelors degree, your admissions requirements will look pretty similar to any other degree requirements. Youll take the SAT/ACT, write a few essays, turn in your transcripts, and hope for the best!

But here are a few things you can do to optimize your chances at getting into the best program possible:

Below youll find the 10 Best Biotechnology degrees. We took a number of steps to find our list. First, we gathered the academic quality of each program. Then we looked at affordability and the return on investment a big factor in how you decide on a school. Last but not least, we factored in student happiness using retention rates and graduation rates of each program.

Our methodology draws from our data team at College Choice, the quality resources at U.S. News & World Report, and the statistics at Payscale.com. Heal the world and feed the world with a degree in Biotechnology!

See our rankings methodology page.

Read the original post:
10 Best Biotechnology Degrees - College Choice

I recently got my proposal rejected by the SBIR program. What bothered me the most was that all three had failed to cite any fundamental issues with the scientific merit of the study. Their resins for rejection were as follows:

Proposed PI does not hit a Ph.D in the field for which he describes his research.

Lab facilities that had agreed to host the proposers research do not explicitly list the presence of electron microscopes

PI did not outline his strategy for addressing regulatory hurdles in bringing the proposed construct to market.

PI did not cite any prior, existing relationships with partners capable of navigating the regulatory space.

Project leans on two fashionable areas of research and fails to demonstrate significant market need.

PI cites click-chemistry as one of the methods employed in the research but lacks anyone on the project team with direct experience in said method.

It felt really discouraging to read through the reviewer opinions, because they attacked the project at at places that (in my opinion) dont have as much weight as the research itself. The hypothesis was built on a solid review of over 30 primary sources and the reviewers barely said anything about the actual science of it.

I guess Im not ready to bury this thing yet and wanted to know if there were other, international funding sources I could resubmit to.

Read the original:
Biotech - Engineering Biology to Service Us

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Biotechnology Algae Cultivation Process (Micro Algae) Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Biotechnology Algae Cultivation Process (Micro Algae) market.

The research study includes the latest updates about the COVID-19 impact on the Biotechnology Algae Cultivation Process (Micro Algae) sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Biotechnology Algae Cultivation Process (Micro Algae) manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=375531&utm_source=3WN&utm_medium=888

The Biotechnology Algae Cultivation Process (Micro Algae) market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Biotechnology Algae Cultivation Process (Micro Algae) market.

This study analyzes the growth of Biotechnology Algae Cultivation Process (Micro Algae) based on the present, past and futuristic data and will render complete information about the Biotechnology Algae Cultivation Process (Micro Algae) industry to the market-leading industry players that will guide the direction of the Biotechnology Algae Cultivation Process (Micro Algae) market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Biotechnology Algae Cultivation Process (Micro Algae) market. Additionally, it includes a share of each segment of the Biotechnology Algae Cultivation Process (Micro Algae) market, giving methodical information about types and applications of the market.

Reasons for Buying Biotechnology Algae Cultivation Process (Micro Algae) Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Biotechnology Algae Cultivation Process (Micro Algae) market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=375531&utm_source=3WN&utm_medium=888

In the end, the Biotechnology Algae Cultivation Process (Micro Algae) market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Biotechnology Algae Cultivation Process (Micro Algae) market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Body Wash and Shower Gel Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Blood Glucose Monitoring Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Bisoprolol Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Bitterness Suppressors and Flavor Carriers Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Blood Collection, Processing, Management Devices and Consumables Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See original here:
Biotechnology Algae Cultivation Process (Micro Algae) Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

There is an unexpected shift in the world, and many sectors are experiencing thoughts triggered by the COVID-19 pandemic. The outbreak of COVID-19 has had a positive impact on the demand for chromatography. In the pharmaceutical industry, chromatography technology is commonly used for the detection of cancer cells. It is also used for drinking water and air processing, plasma fractionation, enzyme purification, and purification. The Environmental Authority, for example, listed chromatography as safe for the measurement of drinking water purity as a means of easy propagation of the coronavirus through polluted water. During this coronavirus crisis, we are helping our clients in understanding the impact of COVID-19 on the chromatography system market.

Our report includes:

A new report by Research Dive states that the global chromatography system market is set to grow at a CAGR of 6.9% and is projected to garner a revenue of $16,304.0 million during the period of forecast from 2019 to 2026. The report delivers in-depth insights into opportunities, vital segments, restraints, drivers, and prominent players of the global market. Based on the type, end-use, and region of the global market segmentation. The report offers insights on drivers, opportunities, restraints, analysis of segment, and competitive market players. Increasing the use of chromatography methods in the pharmaceutical industry is a significant factor for market growth, according to our analysts. Nonetheless, due to the existence of capillaries for the oxygen, hydrogen, and methane separation, a requirement of qualified professionals and high construction costs and maintenance costs is anticipated to impede the growth of the market for the chromatography device. The global market is segmented on the basis of type, end-use industry, and region.

Check out How COVID-19 impact on the Chromatography Systems Market. Click here to Connect with Analyst @ https://www.researchdive.com/covid-19-insights/207/chromatography-system-market#myQueryForm

Pharmaceutical and biotechnology Segment to be the Most Lucrative

The chromatography device market is categorized on the basis of end-use application into hospitals and medical, pharmaceutical, and biotechnology industries and the food and agriculture industry. The demand for pharmaceuticals and biotechnology is projected to rise by 7.3% CAGR, with $5,651.4 million anticipated by 2026. The need for highly sensitive product information in terms of quality and purity, increased use of biopharmaceuticals, especially bio-similar medicines, and monoclonal antibodies that are expected to drive the need for chromatography system are all contributing to the size of the market in the prediction time frame.

The world market share for Asia-Pacific is prominent and is projected to hit $3,283.9 million by 2026 @ https://www.researchdive.com/covid-19-insights/207/chromatography-system-market

Asia-Pacific Region to Expand Business at a Considerable Growth Rate

The world market share for Asia-Pacific is prominent and is projected to hit $3,283.9 million by 2026. The rise in research activities in different fields, such asbiological innovation and pharmaceutical purpose, has contributed to this dominance. A substantial increase is expected to result in sales of $3,283.9 million by 2026, with a 7.5% CAGR in demand for Asia-Pacific RO water treatment system components. In Asia-Pacific, this anticipated rise is mainly due to the existence, of several biopharmaceutical research and development centres, in various major companies such as Merck, Eli Lilly, and Pfizers. These factors are anticipated to fuel the growth of the market over time.

Prominent Players of the Market

Some of the key players of the global chromatography system market include Agilent Technologies (NYSE: A), Perkin Elmer, APIX, Thermo Fisher Scientific Inc., Xylem (OI Analytical), CDS Analytical, Shimadzu Corporation, Waters Corporation, Jasco Inc, Bio-Rad Laboratories and others. These players are adopting several strategies such as mergers & acquisitions and novel product developments to improve their company position in the global industry.

About Us:Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact us:Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US)Toll Free: +1-888-961-4454E-mail: [emailprotected]LinkedIn:https://www.linkedin.com/company/research-dive/Twitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-Dive-1385542314927521Blog:https://www.researchdive.com/blogFollow us:https://marketinsightinformation.blogspot.com/

See original here:
Pharmaceutical and biotechnology Segment to be the Most Lucrative in Chromatography Systems Market - Jewish Life News

A rating of 80 puts Immunomedics, Inc. (IMMU) near the top of the Biotechnology industry according to InvestorsObserver. Immunomedics, Inc.'s score of 80 means it scores higher than 80% of stocks in the industry. Immunomedics, Inc. also received an overall rating of 70, putting it above 70% of all stocks. Biotechnology is ranked 13 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 70 would rank higher than 70 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Immunomedics, Inc. (IMMU) stock is trading at $41.15 as of 1:12 PM on Monday, Jul 6, an increase of $3.61, or 9.62% from the previous closing price of $37.54. The stock has traded between $39.22 and $41.40 so far today. Volume today is 3,753,250 compared to average volume of 3,897,633.

To see the top 5 stocks in Biotechnology click here.

Read the original post:
Is Immunomedics, Inc. (IMMU) a Winner in the Biotechnology Industry? - InvestorsObserver

Clinical Decision Support Systems (CDSS) Market Trends By Component (Software), Product (Integrated CDSS), Model (Knowledge-Based CDSS) Delivery Mode (On-Premise CDSS), Mode of Advice (Active CDSS), Setting (Inpatient Setting), Type (Therapeutic CDSS), Application (Advanced CDSS), Growth Opportunity, Size, Demand, Technology and Regional Analysis Global Forecast Till 2023.

The Clinical Decision Support Systems (CDSS) Market Size is set to witness a CAGR of 12%, which projects above-average growth for the global market.

The Clinical Decision Support Systems (CDSS) market is growing significantly over the past few years. The healthcare industry is witnessing a spurting growing due to the ever-increasing population that is prompting the need for effective treatment and care. The Players that leads the global CDSS market include

Request for a FREE [emailprotected]https://www.marketresearchfuture.com/sample_request/6038

By Latest Product launches and investment in R&D are a few of the important strategies employed by the top players in the global market to facilitate growth.

Prominent players analyzed in the report include

Allscripts

Carestream

Agfa-Gevaert Group

Elsevier B.V.

Athenahealth

Hearst Health

Cerner Corporation

Meditech

and Epic Systems Corporation

Wolters Kluwer Health

and among others.

Clinical Decision Support Systems (CDSS) Market Segmentation:

The global CDSS market is segmented into component, product, model, delivery mode, mode of advice, settings, type, application, and region. By component, the market is segmented into services, software, and hardware. Software accounted for the largest share of the market and valued USD 493.43 million in 2017 and is expected to maintain its lead while reaching an evaluation of USD 982.42 million by the end of 2023.

By product, the market is segmented into integrated CDSS and standalone CDSS. Integrated CDSS is found to have the majority share and is expected to grow at the fastest CAGR. Integration allows healthcare professionals to access solutions that are interconnected and share a common user interface and database, thus simplifying the process.

By model, the market is segmented into Knowledge-based CDSS, and Non-Knowledge-based CDSS. Knowledge-based CDSS accounts for the majority share of the market due to the high number of advantages this system has over non-knowledge based CDSS.

By delivery mode, the market is segmented into in-premise and cloud-based systems. With global technology moving toward adoption of cloud-based systems, the healthcare sector is no different. The low capital and operational costs incurred in the implementation of cloud-based systems is highly beneficial as compared to on-premise systems.

By mode of advice, the market is segmented into passive CDSS and active CDSS. The active CDSS segment accounts for the largest share of the market with approximately 75% of the total share.

By settings, the market is segmented into inpatient settings and ambulatory care settings. Inpatient settings account for over 70% of the total market due to the requirement of a large volume of patient data that is captured and analyzed by healthcare professionals.

By type, the market is segmented into therapeutic clinical decision support system and diagnostic clinical decision support system. Due to its ability to transform clinical health practices by providing a user interface with the best therapeutic practices, the therapeutic CDSS segment has the leading market position.

By application, the market is segmented into conventional clinical support systems and advanced clinical decision support system. The advanced CDSS segment accounts for the largest segment with the highest CAGR of 12.34% during the assessment period. Users of CDSS has opting to upgrade conventional systems to include premium functions such as treatment planning protocol, population health management, patient record management, protocol validation, reasoning based models and health economics management too.

Browse Complete Premium Report [emailprotected]https://www.marketresearchfuture.com/reports/clinical-decision-support-systems-market-6038

18 LIST OF TABLES

TABLE 1 PRIMARY INTERVIEWS

TABLE 2 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 20152023 (USD MILLION)

TABLE 3 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR SOFTWARE, BY REGION, 20152023 (USD MILLION)

TABLE 4 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR SERVICES, BY REGION, 20152023 (USD MILLION)

TABLE 5 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR HARDWARE, BY REGION, 20152023 (USD MILLION)

TABLE 6 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT, 20152023 (USD MILLION)

TABLE 7 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR INTEGRATED CDSS, BY REGION, 20152023 (USD MILLION)

TABLE 8 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR STANDALONE CDSS, BY REGION, 20152023 (USD MILLION)

TABLE 9 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL, 20152023 (USD MILLION)

TABLE 10 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR KNOWLEDGE-BASED CDSS, BY REGION, 20152023 (USD MILLION)

TABLE 11 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR NON-KNOWLEDGE-BASED CDSS, BY REGION, 20152023 (USD MILLION)

Continued

Contact:

Market Research Future, Pune 411028

Maharashtra, India

+1 646 845 9312

Email:[emailprotected]

See the original post here:
Clinical Decision Support Systems (CDSS) Market Application Products, Applications with Biotechnology and Nature Research Report 2020 - Owned

It is our aim to provide our readers with report for Food Biotechnology Market, which examines the industry during the period 2020 2026. One goal is to present deeper insight into this line of business in this document. The first part of the report focuses on providing the industry definition for the product or service under focus in the Food Biotechnology Market report. Next, the document will study the factors responsible for hindering and enhancing growth in the industry. After covering various areas of interest in the industry, the report aims to provide how the Food Biotechnology Market will grow during the forecast period.

The major vendors covered:

ArcadiaBiosciences, AquaBountyTechnologies, BASFPlantScience, Bayer CropScienceAG, Camson Bio Technologies, DowDuPont, EvogeneLtd, Hy-LineInternational, KWS Group, Monsanto, Origin Agritech, Syngenta AG, etc and more

The final report will add the analysis of the Impact of Covid-19 on Food Biotechnology Market.

Request a free sample copy @ https://www.reportsandmarkets.com/sample-request/global-food-biotechnology-market-size-status-and-forecast-2018-2025?utm_source=primefeed&utm_medium=38

The Food Biotechnology Market report between the years 2020 2026 will highlight the current value of the industry. At the same time, there is also an estimate of how much this line of business will be worth at the end of the forecast period. As it is our goal to maintain high levels of accuracy at all times, we will take a look at the CAGR of the Food Biotechnology Market. We make sure that all the information available in this report has excellent levels of readability. One way we achieve this target is by Food Biotechnology Market segmentation. Going through the report for 2020 2026 will bring our readers up-to-date regarding this industry.

While examining the information from this document, one thing becomes clear, the elements which contribute to increase in demand for the product or service. At the same time, there will be a focus on what drives the popularity of these types of products or services. This report is for those who want to learn about Food Biotechnology Market, along with its forecast for 2020 2026. Information regarding market revenue, competitive partners, and key players will also be available.

Segmentation

As discussed earlier, there is segmentation in the Food Biotechnology Market report, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Food Biotechnology Market. At the same time, there is emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Food Biotechnology Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of the Food Biotechnology Market report, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows Middle East and Africa, South and North America, Europe, and Asia Pacific. From the Food Biotechnology Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From this Food Biotechnology Market report, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Food Biotechnology Market report.

If you have any special requirements about this Food Biotechnology Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.reportsandmarkets.com/enquiry/global-food-biotechnology-market-size-status-and-forecast-2018-2025?utm_source=primefeed&utm_medium=38

About Us

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

View post:
2020 Impact of COVID-19 on Food Biotechnology Size, Share, Growth, Demand and Forecast to 2026 - Owned